Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma
LUNG CANCER, cilt.57, sa.1, ss.79-83, 2007 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 57 Sayı: 1
- Basım Tarihi: 2007
- Doi Numarası: 10.1016/j.lungcan.2007.02.009
- Dergi Adı: LUNG CANCER
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.79-83
- İstanbul Üniversitesi Adresli: Evet
Özet
Background: Topotecan is an active agent for the management of untreated and recurrent extensive-disease small cell tung cancer, (ED-SCLC). This study was designed to evaluate the efficacy and safety of a triplet combination with topotecan added to the standard PE regimen in previously untreated patients with ED-SCLC.